Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) have earned an average recommendation of “Moderate Buy” from the six analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $24.25.

A number of research analysts have recently commented on the company. Oppenheimer began coverage on Adlai Nortye in a report on Thursday, May 28th. They issued an “outperform” rating and a $32.00 price objective on the stock. Cantor Fitzgerald started coverage on shares of Adlai Nortye in a research report on Monday, June 22nd. They set an “overweight” rating on the stock. Wall Street Zen raised Adlai Nortye from a “hold” rating to a “buy” rating in a report on Saturday, August 22nd. JonesTrading started coverage on shares of Adlai Nortye in a research note on Thursday, May 14th. They set a “buy” rating and a $22.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Adlai Nortye in a research report on Tuesday, July 14th.

Adlai Nortye Stock Performance

Shares of ANL stock opened at $15.01 on Friday. Adlai Nortye has a 52 week low of $0.88 and a 52 week high of $17.25. The company has a debt-to-equity ratio of 0.04, a current ratio of 9.55 and a quick ratio of 0.65. The firm has a 50 day moving average of $12.55 and a two-hundred day moving average of $11.37.

Insider Activity

In other news, CFO Xiaofeng Ye sold 6,000 shares of the business’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $13.98, for a total value of $83,880.00. Following the completion of the transaction, the chief financial officer directly owned 153,424 shares of the company’s stock, valued at $2,144,867.52. The trade was a 3.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. SmartHarvest Portfolios LLC raised its position in shares of Adlai Nortye by 8.5% in the first quarter. SmartHarvest Portfolios LLC now owns 16,367 shares of the company’s stock valued at $113,000 after buying an additional 1,279 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Adlai Nortye in the 1st quarter valued at $457,000. Seven Fleet Capital Management LP acquired a new position in Adlai Nortye in the 2nd quarter valued at $1,302,000. ADAR1 Capital Management LLC purchased a new position in shares of Adlai Nortye during the 1st quarter worth $816,000. Finally, Affinity Asset Advisors LLC acquired a new stake in shares of Adlai Nortye during the first quarter worth $1,140,000. Institutional investors and hedge funds own 35.21% of the company’s stock.

Adlai Nortye Company Profile

Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.

Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.

The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.